J&J Innovation: Tapping the innovation spigot

July 23, 2015 Erin Righetti

BuzzbuzzIn June, Johnson & Johnson Innovation announced in a press release 17 new collaboration deals that would effectively expand their successful research incubator model to Europe, Canada and China. The new collaborations with research institutions and healthcare companies bring the total collaborations formed to 200.

J&J Innovation is a trend setter. It’s not news that pharma companies are increasingly looking outside themselves to access, cultivate and capture innovation to translate into new pipelines. What’s truly trend setting is the way that J&J Innovation has helped to shape the new biotech investment model and approach from myopic revenue-based deals to flexible, early-entry translational medicine collaborations that end up a win-win for all parties, even those in academia.

Another big reason why the incubator model works? Community. If you have toured a J&J Innovation hub location, you know that the excitement of collaboration focused on discovery is a tangible asset. You’ll likely find happy scientists, excited staff, and state-of-the-art lab and meeting spaces filled with buzzing activity. It’s attractive, effective and compelling. People thrive where like-minded people are gathered, and the energy is contagious.

Finally, J&J Innovation knows something that is best expressed by the old adage: “There are three things that matter in property: location, location, location.” Be where the innovation is, congregate close to the source, and work with startups to facilitate the connections that will end up the next wave of lifesaving drugs and technologies.

Robert Urban, head of J&J Innovation in Boston, said in a July 9 BioCentury article: “The innovation centers are hotspots for life science innovation where senior technology people from J&J are allocated from across the different sectors of the company to interact with the scientific community and make different forms of deals to promote development of new technology, create new spinout companies or in-license technology into J&J for development.”

In other words, J&J Innovation knows how to tap the innovation energy spigot, they’re darn good at it, and they’re expanding.

Want to hear more about J&J Innovation or request a meeting with them? Register for BioPharm America. It’s an event you don’t want to miss.
J&J Innovation is a Platinum Sponsor of BioPharm America international life science partnering conference taking place September 15–17 at Boston Marriott Copley Place in the center of Boston’s historic Back Bay. They are also sponsors of Biotech Startup Day during BioPharm America, a day specifically designed for early stage projects and young companies to get on the radar of and connect with the global life science community and specifically, with Boston’s leading financiers, pharma dealmakers and biotech business KOLs.


Erin Righetti is Editor of partnering360® Blog. Any views expressed are hers and not those of Informa.

Previous Article
BMT publishes its quarterly outlook report
BMT publishes its quarterly outlook report

Guest post by Robert Jeng, Senior Scientific Analyst, BioMedTracker BioMedTracker (BMT) has once again publ...

Next Article
Patient-centric Baxalta capitalizes on Cambridge
Patient-centric Baxalta capitalizes on Cambridge

When Baxalta Incorporated spun out of Baxter on July 1, it already qualified as "big pharma." With USD 6 bi...